Amgen Seeks To Leave ESA Woes Behind In 2009

Aranesp sales are stabilizing, and Amgen expects to enter the new year with “steady-state” ESA sales, management says.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet